Taiwan
· Delayed Price · Currency is TWD Medigen Biotechnology Statistics
Total Valuation
Medigen Biotechnology has a market cap or net worth of TWD 4.97 billion. The enterprise value is 6.79 billion.
| Market Cap | 4.97B |
| Enterprise Value | 6.79B |
Important Dates
The next estimated earnings date is Tuesday, November 12, 2024.
| Earnings Date | Nov 12, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Medigen Biotechnology has 139.23 million shares outstanding. The number of shares has increased by 0.17% in one year.
| Shares Outstanding | 139.23M |
| Shares Change (YoY) | +0.17% |
| Shares Change (QoQ) | +0.05% |
| Owned by Insiders (%) | 6.56% |
| Owned by Institutions (%) | 4.26% |
| Float | 109.13M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 3.57 |
| PB Ratio | 2.97 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -15.67 |
| EV / Sales | 4.87 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -30.72 |
Financial Position
The company has a current ratio of 3.60, with a Debt / Equity ratio of 19.74.
| Current Ratio | 3.60 |
| Quick Ratio | 2.92 |
| Debt / Equity | 19.74 |
| Debt / EBITDA | n/a |
| Debt / FCF | -4.55 |
| Interest Coverage | -15.26 |
Financial Efficiency
Return on equity (ROE) is -17.58% and return on invested capital (ROIC) is -6.84%.
| Return on Equity (ROE) | -17.58% |
| Return on Assets (ROA) | -6.29% |
| Return on Capital (ROIC) | -6.84% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.17 |
| Inventory Turnover | 0.72 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +6.23% in the last 52 weeks. The beta is 0.57, so Medigen Biotechnology's price volatility has been lower than the market average.
| Beta (5Y) | 0.57 |
| 52-Week Price Change | +6.23% |
| 50-Day Moving Average | 39.08 |
| 200-Day Moving Average | 41.72 |
| Relative Strength Index (RSI) | 29.72 |
| Average Volume (20 Days) | 101,478 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Medigen Biotechnology had revenue of TWD 1.39 billion and -433.07 million in losses. Loss per share was -3.11.
| Revenue | 1.39B |
| Gross Profit | 791.99M |
| Operating Income | -807.12M |
| Pretax Income | -764.54M |
| Net Income | -433.07M |
| EBITDA | -655.04M |
| EBIT | -807.12M |
| Loss Per Share | -3.11 |
Balance Sheet
The company has 2.60 billion in cash and 1.00 billion in debt, giving a net cash position of 1.60 billion or 11.47 per share.
| Cash & Cash Equivalents | 2.60B |
| Total Debt | 1.00B |
| Net Cash | 1.60B |
| Net Cash Per Share | 11.47 |
| Equity (Book Value) | 5.09B |
| Book Value Per Share | 12.03 |
| Working Capital | 2.70B |
Cash Flow
In the last 12 months, operating cash flow was -183.10 million and capital expenditures -37.85 million, giving a free cash flow of -220.95 million.
| Operating Cash Flow | -183.10M |
| Capital Expenditures | -37.85M |
| Free Cash Flow | -220.95M |
| FCF Per Share | -1.59 |
Margins
Gross margin is 56.84%, with operating and profit margins of -57.93% and -31.08%.
| Gross Margin | 56.84% |
| Operating Margin | -57.93% |
| Pretax Margin | -54.87% |
| Profit Margin | -31.08% |
| EBITDA Margin | -47.01% |
| EBIT Margin | -57.93% |
| FCF Margin | -15.86% |
Dividends & Yields
Medigen Biotechnology does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.17% |
| Shareholder Yield | -0.17% |
| Earnings Yield | -8.71% |
| FCF Yield | -4.45% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |